Mr. Ken Powell
President, Genesis Business Development, LLC
Member of the Healthcare Council
Council Member Biography
Ken Powell is the President of Genesis Business Development, a healthcare consultancy. Mr. Powell has experience in the identification, acquisition, and commercialization of intellectual property, new businesses, and products in the clinical diagnostics and medical device market segments. He has knowledge about emerging technologies, personalized medicine, diagnostic test kits, medical devices, clinical laboratory systems, point of care, genomics, proteomics, life sciences, lab distributors, and molecular diagnostic markets. Mr. Powell is also knowledgeable about evolving molecular diagnostic regulatory (FDA, CLIA, Congressional) and reimbursement issues. He has held senior management positions with Becton Dickinson, Roche Diagnostics, Technicon, Armour Pharmaceuticals, and Upjohn Clinical Laboratory Procedures. Mr. Powell is conversant in all aspects of diagnostic and life sciences segments and their relationship to current and emerging companies. (This is me - Update Profile)
Employment History
- 2006 - Unspecified
- President, Genesis Business Development, LLC
- 1986 - 2006
- Director of Business Development, BECTON, DICKINSON AND COMPANY
- 1984 - 1986
- Director of Marketing, Revlon Healthcare
- 1982 - 1983
- Senior Product Manager, Becton Dickinson Immunodiagnostics
- 1976 - 1982
- Product Manager, ROCHE DIAGNOSTICS CORPORATION
GLG NewsSM Analyses by Ken Powell(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Will Quest Acquire Vermillion?
November 20, 2009
Why Quest Will Acquire Vermillion | www.genomeweb.com
Quest Diagnostics has had a known relationship with Vermillion. Now that Vermillion has received FDA approval for its OVA1 in vitro diagnostic multi-variant index assay (IVDMIA) and Quest has an exclusive three year marketing license and a 17% investment in the company plus additional loans, acquisition of Vermillion could make sense for both companies.
-
Roche Receives H1N1 FDA Emergency Use Authorization
November 16, 2009
Roche Gets FDA EUA for H1N1 Test Kit | www.genomeweb.com
Roche has received an Emergency Use Authorization from the FDA for its RealTime ready Influenza A/H1N1 Detection Set. The new H1N1 assay is run on its MagNA Pure LC platform for nucleic acid isolation and its LightCycler 2.0 system for real-time PCR applications. Roche, the worldwide clinical diagnostics leader should have an advantage in the H1N1 market segment.
-
November 14, 2009
Sequenom Shareholders Sue Company, Officials over SEQureDx Data Mishandling | www.genomeweb.com
The Sequenom sage appears endless. Following the "mishandling of data" involving the company's Down's syndrome test, termination of company executives, investigation by the NASDAQ , the SEC and the US Attorney for the Southern District of California, Xenomics lawsuit against Sequenom seeking up to $300 million in damages, Sequenom shareholders have filed a suit against the company and several individual current and former executives . The news continues to mount and none of it is good.
-
Epigenomics Reports Excellent 3Q Returns
November 12, 2009
Epigenomics Nearly Quadruples Sales in Q3 | www.genomeweb.com
Germany based Epigenomics posted stellar Q3 financial results and reduced net loss by 8%. According to the company, the increase comes from existing collaborations, new partnerships, and license agreements
-
November 12, 2009
Life Technologies to Buy Biotrove, Which Will Form Mass Spec Sample Prep Company | www.biotrove.com
Following on Life Technologies' (NASDAQ: LIFE) acquisition of Biotrove, Biotrove announced in a separate release that it will form a subsidiary for a sample handing company for mass spectroscopy systems. This could be the real opportunity for future growth.
Leading institutions connect with Ken Powell through GLG
GLG Study Groups with Ken Powell(?)
| Study Group Name | No. Members |
|---|---|
| Experts in the Leisure & Lodging Council | 4887 |
| Experts in the Automotive Council | 3422 |
| Economic Experts on Managed Care | 714 |
| Medical Device Experts | 317 |
| Medical Geneticists (US) | 85 |
GLG Live Meetings with Ken Powell(?)
Ken Powell has not participated in any GLG Live Meetings.